Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225816 · ClinicalTrials.gov registry record · Phase 1

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

A Phase 1 study of Obesity, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
75
Enrollment target
1
Study location

NCT07225816 is a Phase 1 study of Obesity that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 75 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225816, a Phase 1 study of Obesity, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

Conditions Studied

Obesity

Interventions

  • DRUG Semaglutide
  • DRUG Liraglutide
  • DRUG Oral Semaglutide

Study Locations (1)

California

  • Altasciences Clinical LA, Inc. - Cypress

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-11-07
Est. Completion 2026-07-17
Phase Phase 1

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07225816

The ClinicalTrials.gov registry entry for NCT07225816 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Semaglutide is the first listed.

NCT07225816 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07225816 about?

NCT07225816 is a clinical study titled "Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)". The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of pa...

What is the current status of trial NCT07225816?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-11-07. Estimated completion is 2026-07-17.

What conditions does trial NCT07225816 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT07225816?

The interventions under investigation include: Semaglutide (DRUG), Liraglutide (DRUG), Oral Semaglutide (DRUG).

Who is sponsoring clinical trial NCT07225816?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225816 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.